Novo Nordisk said CagriSema was linked to 25% weight loss in women in new analysis
- Novo Nordisk: 18 events in the last 90 days
- Previous: 3 days earlier · Novo Nordisk is suing Eli Lilly over ads it says mislead consumers on weight loss drug efficacy
What happened
The post hoc analysis of the REDEFINE 1 trial found average losses of 23.1% to 26.7% across menopause stages
Summary assembled by rule from the sources below